AndroGel 1.62% treatment is approved for patients with primary or secondary adult male hypogonadism due to an associated medical condition.1

Primary hypogonadism1,3

  • Defined as low testosterone resulting from testicular defect
  • Characterized by low testosterone and elevated LH and FSH levels

Associated medical conditions
of primary hypogonadism1

  • Klinefelter’s syndrome
  • Bilateral torsion
  • Chemotherapy
  • Orchitis
  • Cryptorchidism
  • Vanishing testis syndrome
  • Toxic damage from alcohol or
    heavy metals
  • Orchiectomy

This is not an exhaustive list of conditions.

Secondary hypogonadism1,3

  • Defined as low testosterone resulting from pituitary or hypothalamic defect
  • Characterized by low testosterone and LH and FSH levels that are low or normal

Associated medical conditions of secondary hypogonadism1

  • Gonadotropin or luteinizing
    hormone-releasing hormone
    (LHRH) deficiency
  • Pituitary-hypothalamic injury
    • Tumors
    • Trauma
    • Radiation

This is not an exhaustive list of conditions.

Limitations of use:

  • Safety and efficacy of AndroGel 1% and 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.
  • Safety and efficacy of AndroGel in males less than 18 years old have not been established.
  • Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure.

Prior to initiating therapy
with AndroGel 1.62%

  • Confirm specific etiology:

    If hypogonadism is suspected, identify the underlying medical condition that is causing it1

  • Perform 2 blood tests:

    Confirm a diagnosis of hypogonadism by performing two tests of morning serum total testosterone level on separate days1